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The term Endocrine Related Cancers 
 classically includes a group of sex steroid 
responsive cancers, such as cancers of the 
breast, endometrium, prostate, and testis, 
but also other cancers such as thyroid and 
ovary cancers that are responsive to pitui-
tary hormones (1). Based on this widely 
accepted concept, at least 35–40% of newly 
diagnosed cancers fall into this definition 
(2). This concept has been useful for its 
clinical implications, and has lead to the 
use of anti-estrogenic/anti-androgenic 
treatments for sex hormone responsive 
cancers, as well as to thyroid-stimulating 
hormone (TSH) suppressive therapy with 
l-thyroxine (l-T4) for differentiated thy-
roid cancer. Moreover, several studies have 
tried to identify physiological conditions, 
such as early menarche, late menopause, 
age of first pregnancy, and number of preg-
nancies, prolonged lactation, and obesity, 
that may all affect sex steroids availabil-
ity/exposure and modulate cancer risk. 
Another series of studies have identified 
germline polymorphisms, which are linked 
to the modulation of cancer risk through 
the genetic control of serum hormone lev-
els or target tissue responses (3). Finally, 
other studies have addressed the possi-
ble effects of the exposure to exogenous 
sex hormones, such as estroprogestins 
(4) or postmenopausal estrogen replac-
ing therapy (5) or endocrine disruptors 
(6). While all these studies have provided 
useful information for cancer prevention 
and treatment, our understanding of how 
genetic traits relevant to hormone action, 
control and interaction with physiological 
conditions, hormonal supplementations, 
and environmental factors is still limited. 
Another grand challenge is represented 
by the possibility to achieve effective and 
risk-free chemoprevention for  subjects 
predisposed to individual endocrine 
related cancers, as exemplified by the use 
of tamoxifen and other agents in breast 
cancer predisposed subjects (6).
In recent years, several studies have 
challenged this classical view of endocrine 
related cancer. We now summarize recent 
data, which should be taken into account 
to reformulate the term “endocrine related 
cancer” in a more expanded way.
Sex Steroid HormoneS and 
CanCer: a Broad View
non-ClaSSiCal effeCtS eliCited By 
ClaSSiCal Sex Steroid reCeptorS and 
non-ClaSSiCal eStrogen reCeptorS
Non-classical effects activated by androgen 
and estrogen receptors
It is well-established that a small propor-
tion of canonical sex steroid receptors are 
located at the cell membrane. Upon cell 
stimulation by either estrogens or andro-
gens, they form multiprotein complexes at 
the cell membrane that activate the Src/
ERK/PI3K pathways (7). This pathway is 
named MISS (membrane-initiated ster-
oid signaling) and may be upregulated 
in cancer cells for a number of reasons, 
among which increased location of sex 
steroid receptors at the cell membrane 
and increased expression of adaptor 
proteins, which favor the formation of 
multiprotein complexes containing Src 
(7). The activation of the Src/ERK/CREB 
pathway by MISS may enhance the activa-
tion of IGF system in prostate cancer (8). 
Intriguingly, MISS are scarcely inhibited 
by classical anti-hormone therapy, which 
preferentially blocks the genomic pathway. 
The occurrence of MISS in cancer should 
be more widely investigated as a poten-
tial new target to prevent resistance to 
anti-hormone therapy.
Non-classical receptors of steroid hormones 
involved in cancer
While classical estrogen receptors (ERα 
and ERβ) may elicit both canonical 
genomic effects and MISS, a member of 
the seven-transmembrane G protein-
coupled receptor family, GPER, may also 
mediate both rapid and transcriptional 
events in response to estrogens, especially 
in cancer cells (9). GPER is expressed in 
both ER-positive and ER-negative breast 
carcinoma cells, and in a variety of other 
cancer cells including endometrial, cho-
riocarcinoma, ovarian, and thyroid cancer 
cells (10). Accumulating evidence supports 
the notion that GPER may contribute to 
carcinogenesis and to resistance to anti-
estrogen therapy. Noteworthy, the partial 
ER antagonist tamoxifen behaves as a GPER 
agonist (11) suggesting that conventional 
anti-estrogens may contribute to clonal 
selection of cancer cells. In ER-negative 
and tamoxifen-resistant breast cancer cells, 
significant cross-talk exists between both 
EGF and IGF pathways and GPER expres-
sion and signaling (10). GPER expression 
in cancer, ER/GPER cotargeting by novel 
inhibitors, and GPER cross-talk with IGF 
axis need to be further explored (10, 12). 
Interestingly, endocrine disruptors, such as 
Bisphenol A (13) or Cadmium, may induce 
estrogen like effects via GPER (14).
metaBoliC diSorderS and CanCer: tHe 
role of “metaBoliC HormoneS” in CanCer 
related tumorS
Insulin, a new cancer related hormone
Overwhelming evidence now indicates that 
both obesity and type 2 diabetes mellitus 
(T2DM) are associated with up to two to 
threefold increased risk for various malig-
nancies (15). Insulin resistance and com-
pensatory hyperinsulinemia, present in 
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A cancer role for other metabolic hormones?
Accumulating evidence indicate that hor-
mones secreted by non-classical endocrine 
organs may affect cancer risk through both 
direct and indirect mechanisms. Indirect 
mechanisms often act through the modu-
lation of insulin secretion and sensitivity, as 
well as sex hormones secretion and metabo-
lism. Leptin and adiponectin are two adi-
pokines extensively studied in relationship 
to cancer (29).
Obesity is characterized by leptin resist-
ance and increased leptin levels, and by 
reduced levels of circulating adiponectin. 
Receptors for both adipokines are present 
in cancer cells. Leptin may promote cancer 
both directly and by increasing aromatase 
expression and estrogen production (30). 
In contrast, circulating concentrations 
of adiponectin are inversely related to 
increased risk for a variety of malignancies. 
Adiponectin may also act directly on cancer 
cells but may also contribute to ameliorate 
insulin sensitivity and decrease circulating 
insulin levels (29).
Recently, a complex relationship 
between bone metabolism with glucose 
metabolism and sex steroid metabolism 
has been found. For instance, an osteoblast 
secreted protein, osteocalcin, affects insulin 
production and sensitivity and testosterone 
production (31). Moreover, low level of the 
steroid hormone vitamin D, is also impli-
cated in worsening of insulin resistance and 
increased aromatase activity (31).
How this complex interplay between var-
ious metabolic hormones can be integrated 
in the concept of hormone sensitive cancer 
is still undefined. Moreover, how and to 
what extent this network may be modulated 
by diet and lifestyle or by pharmacological 
interventions in order to reduce cancer risk 
is still an open question.
tHe tHyroid model in endoCrine 
onCogeneSiS
Thyroid gland function and trophism are 
mainly regulated by TSH, which is the key 
player of thyrocyte differentiation and pro-
liferation. TSH has a well-known promot-
ing role for differentiated thyroid cancer 
metastases, and TSH suppressive therapy 
with l-thyroxine, a well-established ther-
apy in the postoperative management of 
differentiated thyroid cancer. However, to 
exert its maximal mitogenic and protumo-
rigenic effects, TSH requires concomitant 
patients could be cancer growth promotion 
and resistance to anti-androgen treatment. 
This possibility is presently underscored 
and deserves to be further explored. With 
regard to breast cancer patients receiving 
anti-estrogen therapies, contradictory data 
exist concerning patients using tamoxifen, 
although they usually present with liver ste-
atosis (25), a well-known complication of 
insulin resistance. Moreover, insulin resist-
ance is a common finding in patients treated 
with aromatase inhibitors (26).
Development of insulin resistance is a 
major side effect of cancer target therapy 
with IGF-IR blocking agents and may con-
tribute to the dismal results of clinical trials 
employing these agents (19).
Development of insulin resistance in the 
course of cancer treatment should be now 
considered a factor that may significantly 
interfere with efficacy of treatment itself. 
We need, however, a new strategy to pre-
dict the individual risk of insulin resistant 
patients, including those receiving chronic 
therapies with drugs that worsen insulin 
resistance, not only in terms of metabolic 
complications, but also in terms of cancer 
risk or cancer resistance to therapy. The use 
of large-scale omics analyses (e.g., metabo-
lomic, proteomic, transcriptomic, and lipi-
domic) may perhaps help to identify such 
new strategies.
Antidiabetic therapy and cancer
Antidiabetic drugs may modulate insulin 
sensitivity and/or circulating insulin lev-
els. Insulin sensitizers, like metformin are 
associated with decreasing insulin levels, 
while administration of insulin secretion 
modulators or of exogenous insulin is often 
associated with non-physiological circulat-
ing insulin levels. Insulin analogs, which are 
now widely used in diabetes therapy, may 
elicit biased insulin effects at cellular levels 
(27). Epidemiological studies addressing 
the link between the use of specific insulin 
analogs and cancer risk are so far incon-
clusive and face various interfering factors, 
including the heterogeneity of the diabetic 
population (28). Also, preclinical stud-
ies with insulin analogs have not reached 
uniform conclusions. We also need more 
studies exploring the safety of specific anti-
diabetic drugs, such as PPARγ agonists and 
GPL-1 analogs and DPP4 inhibitors. Again, 
the use of large-scale omics analyses may 
hopefully be helpful in this context.
these two disorders, appear to be the major 
determinants of this increased cancer risk 
(16) and are also associated to poor cancer 
prognosis. Although the underlying mecha-
nisms are not fully clarified, two relevant 
factors are represented by the high level of 
circulating insulin and the biased insulin 
action in the presence of insulin resistance 
(17). A third factor is represented by insulin 
receptor (IR) overexpression by most can-
cers (17). Noteworthy, cancer cells overex-
press the isoform A of IR (IR-A), which is 
predominantly expressed in embryo and 
fetal tissues, where it contributes to insulin 
and IGF-II mediated growth and develop-
ment (18).
Although the degree of insulin resist-
ance has a genetic basis, it is greatly modu-
lated by diet and lifestyle. In fact, the rising 
occurrence of obesity and T2DM in western 
countries, and in the developing world, is 
causally associated with changing diet and 
lifestyle. Therefore, insulin resistance has 
become a major preventable cancer risk 
factor (19).
Chronic drug therapies and insulin 
resistance
In this context, it is increasingly recognized 
that a variety of chronic drug therapies, 
including oncologic treatments may cause 
or worsen insulin resistance. Whether they 
affect cancer risk or cause resistance to 
oncologic treatment should be addressed 
by future studies.
For instance, antipsychotic drugs can 
induce weight gain, insulin resistance, and 
other components of the metabolic syn-
drome (20). Some antidepressants, such 
as noradrenergic and tricyclic antidepres-
sants, and antiepileptic drugs may also 
cause insulin resistance (21). Conventional 
chemotherapy, such as cisplatin-based 
chemotherapy, may also be associated 
with increased visceral adipose tissue, 
insulin resistance, and dyslipidemia (22). 
Conversely, IGF-I/Insulin signaling is asso-
ciated with cisplatin resistance (23).
Moreover, anti-androgen and anti-
estrogen therapies may be associated with 
worsening of insulin resistance. Anti-
androgen therapy, besides being associated 
with well-established complications of male 
hypogonadism, is also associated with the 
development or worsening of insulin resist-
ance and T2DM (24). A subtle consequence 
of chronic hyperinsulinemia in these 
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metabolic hormone such as insulin, and 
possibly other metabolic hormones. We 
need better definitions, and better assess-
ment of what hormone sensitivity means 
for individual cancer histotypes. This 
should bring about a consistent shift in 
our concept of “hormone sensitive” cancer, 
and has several relevant implications. New 
models of carcinogenesis should then incor-
porate mechanisms of hormonal action 
in cancer initiation and progression and 
should identify critical ages for hormonal 
carcinogenesis. As far as cancer treatment is 
concerned, the possibility exists that most 
cancer histotypes will be considered ame-
nable to some form of hormone treatment 
in the near future.
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involvement of adipokines, like leptin and 
 adiponectin, should be addressed by future 
studies.
Intriguingly, the incidence of differen-
tiated thyroid cancer is increasing more 
rapidly than that of other cancers in the 
United States (39) and in many countries 
worldwide, with no obvious explanation. 
It is likely that thyroid cancer will continue 
to offer a fascinating model of endocrine 
related cancer to study the complex rela-
tionship between cancer risk and TSH, 
insulin/IGFs and estrogens, but also the 
interplay of these hormonal factors with 
iodine intake, thyroid autoimmunity, and 
other environmental factors like endocrine 
disruptors.
modelS of CarCinogeneSiS: wHat plaCe 
for HormoneS?
The increased awareness that hormones 
may modulate the risk and progression of 
most cancers poses the question of how 
hormone action fits into a general model 
of carcinogenesis. It is generally accepted 
that hormones may enhance the effects of 
mutagens or of spontaneous mutations by 
accelerating proliferation and inhibiting 
apoptosis of mutated cells (3). However, 
there is increasing evidence that epigenetic 
changes have an important role in the car-
cinogenetic process. Indeed, hormones 
do cause epigenetic changes, especially 
at critical ages, such as pre- and perina-
tal life (40). Actually, epigenetic changes 
may explain cancer resistance to endo-
crine therapy (41). Recently, the stem cell 
model of carcinogenesis has been extended 
to solid tumors (42). Hormones, includ-
ing insulin/IGFs, do affect stem cell biol-
ogy and stem cell carcinogenesis (43). 
Unbalanced hormone production, favored 
by nutritional and/or various environmen-
tal factors, may expand the stem cell pool 
at perinatal age, thus affecting cancer risk 
at later ages (44). A better understanding 
of these mechanisms may open the way 
to effective cancer prevention. Hopefully, 
advances in all these areas will contribute 
to develop an improved general model of 
carcinogenesis.
ConCluSion and perSpeCtiVeS
Most cancers appear “hormone sensitive” 
at least at some stages of their development 
and/or progression. It is clear now that the 
relevant hormones include also a typical 
 ligand-activated tyrosine kinase receptor 
signaling (32). Activation of the insulin/
IGFs signaling pathway is especially impor-
tant (32, 33). These observations open the 
way to possible clinical implications in the 
management of differentiated metastatic 
thyroid cancer. First, in order to avoid the 
possible side effects of subclinical hyper-
thyroidism induced by suppressive L-T4 
doses, new modalities to block TSH can be 
envisaged. Second, TSH inhibition could be 
associated with inhibition of the insulin/
IGF pathway.
While the promoting effect of TSH on 
metastatic cancer is well-established, only 
recently studies have observed an increased 
risk of thyroid cancer in subjects with serum 
TSH concentrations in the upper normal 
range (34). These observations are consist-
ent with evidence that thyroid cancer risk 
is increased in endemic goiter iodine defi-
cient areas (35). Iodine deficiency, which 
makes the thyroid gland more responsive 
to the mitogenic effect of TSH, has long 
been suspected to be associated with folli-
cular thyroid cancer. However, the relation-
ship between iodine intake and the risk of 
thyroid cancer is probably non-linear and 
further studies are needed to clarify it. 
Intriguingly, increased iodine intake may be 
associated with an increase of autoimmune 
thyroiditis, which in turn, may cause sub-
clinical hypothyroidism and raised serum 
TSH (36). Moreover, Graves’ disease, an 
autoimmune disorder characterized by 
the presence of TSH receptor stimulating 
antibodies (TSHR-Abs) has been found to 
be associated with increased thyroid can-
cer risk and thyroid cancer aggressiveness 
(37). TSHR-Abs, however, are heterogene-
ous with regard to serum levels, binding 
characteristics to the TSHR, and biological 
effects in different thyroid cancer patients.
Thyroid follicular cancer cells express 
both classical (ERα and ERβ) and non-
classical (GPER) estrogen receptors, which 
may help explain why thyroid cancer is 
more frequent in females. Moreover, thy-
roid cancer cells and stem-like thyroid cells 
also overexpress the IR and IGF-IR (38), 
which may be involved with the increased 
thyroid cancer risk with obesity and insu-
lin resistance. Preliminary epidemiological 
data suggest that obesity may also be associ-
ated with a less favorable clinicopathologic 
profile of thyroid cancer. Large multi-center 
studies are still needed, and the possible 
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